Cannabinoids and the expanded endocannabinoid system in neurological disorders

Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor

Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633

Molecular characterization of a peripheral receptor for cannabinoids

Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913

Determination and characterization of a cannabinoid receptor in rat brain

Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443

2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711

Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses

Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607

Brain monoglyceride lipase participating in endocannabinoid inactivation

Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373

Microglial and macrophage polarization—new prospects for brain repair

Hu, X., Leak, R. K., Shi, Y., Suenaga, J., Gao, Y., Zheng, P., & Chen, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.207 · Cited by 1,366

CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208

A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol

Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177

Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900

Targeting the endocannabinoid system: to enhance or reduce?

Marzo, V. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 822

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & CEBALLOS, M. L. D. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 801

Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners

Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., & Ueda, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306642200 · Cited by 800

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

Panikashvili, D., Simeonidou, C., Ben‐Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752

The pharmacokinetics and the pharmacodynamics of cannabinoids

Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724

The endocannabinoid system links gut microbiota to adipogenesis

Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691

Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

Galve‐Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 686

Alternatively activated microglia and macrophages in the central nervous system

Franco, R., & Fernández‐Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 674

Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration

Walter, L. M., Franklin, A., Witting, A., Wade, C. B., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 674

Cannabinoid CB2Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 636

Mitochondrial CB1 receptors regulate neuronal energy metabolism

Bénard, G., Massa, F., Puente, N., Lourenço, J., Bellocchio, L., Soria-Gómez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannich, A., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3053 · Cited by 588

Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579

Cannabinoids control spasticity and tremor in a multiple sclerosis model

Baker, D., Pryce, G., Croxford, J., Brown, P., Pertwee, R., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 546

New approaches and challenges to targeting the endocannabinoid system

Marzo, V. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 502

Commensal bacteria make GPCR ligands that mimic human signalling molecules

Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500

Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain

Cristino, L., PETROCELLIS, L. D., Pryce, G., Baker, D., Guglielmotti, V., & Marzo, V. D. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.074 · Cited by 489

Hashish—I

Mechoulam, R., & Shvo, Y. (1963) · Tetrahedron · doi:10.1016/0040-4020(63)85022-x · Cited by 486

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS

Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475

Hypothalamic POMC neurons promote cannabinoid-induced feeding

Koch, M., Varela, L., Kim, J. G., Kim, J. D., Hernández-Nuño, F., Simonds, S. E., Castorena, C. M., Vianna, C. R., Elmquist, J. K., Morozov, Y. M., et al. (2015) · Nature · doi:10.1038/nature14260 · Cited by 457

A cannabinoid link between mitochondria and memory

Hebert-Chatelain, E., Desprez, T., Serrat, R., Bellocchio, L., Soria-Gomez, E., Busquets-Garcia, A., Pagano Zottola, A. C., Delamarre, A., Cannich, A., Vincent, P., et al. (2016) · Nature · doi:10.1038/nature20127 · Cited by 434

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

Sánchez, C., CEBALLOS, M. L. D., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve‐Roperh, I., Huffman, J. W., y Cajal, S. R., & Guzmán, M. (2001) · PubMed · Cited by 422

Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s Disease

Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 410

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407

A Total Synthesis of dl-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish1

Mechoulam, R., & Gaoni, Y. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01092a065 · Cited by 401

Brain cannabinoid CB2 receptors modulate cocaine's actions in mice

Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397

The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy

Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393

GABA production and structure of gadB / gadC genes in Lactobacillus and Bifidobacterium strains from human microbiota

Yunes, R. А., Poluektova, E. U., Dyachkova, M. S., Klimina, K. M., Kovtun, A. S., Averina, O. V., Orlova, V. S., & Даниленко, В. Н. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.10.011 · Cited by 389

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711351114 · Cited by 389

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

Ehrhart, J. C., Obregon, D. F., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 386

Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation

Villapol, S. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 386

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382

Endocannabinoids control spasticity in a multiple sclerosis model

Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A. D., Layward, L., Fezza, F., Bisogno, T., et al. (2000) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378

Endocannabinoids–at the crossroads between the gut microbiota and host metabolism

Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367

Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice

Guida, F., Turco, F., Iannotta, M., De Gregorio, D., Palumbo, I., Sarnelli, G., Furiano, A., Napolitano, F., Boccella, S., Luongo, L., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.001 · Cited by 367

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

Maresz, K. Z., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., Ledent, C. A., Cheng, X., Carrier, E. J., Mann, M. K., et al. (2007) · Nature Medicine · doi:10.1038/nm1561 · Cited by 366

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., PETROCELLIS, L. D., Ullmer, C., Rothenhäusler, B., Perret, C., van Gils, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms13958 · Cited by 362

Interactions between cannabidiol and commonly used antiepileptic drugs

Gaston, T. E., Bebin, E. M., Cutter, G., Liu, Y., Szaflarski, J. P., & Program, T. U. C. (2017) · Epilepsia · doi:10.1111/epi.13852 · Cited by 360

Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo

Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.159145 · Cited by 353

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349

TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus

Chávez, A. E., Chiu, C. Q., & Castillo, P. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2684 · Cited by 348

N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia

Chu, C. J., Huang, S. M., PETROCELLIS, L. D., Bisogno, T., Ewing, S. A., Miller, J. D., Zipkin, R. E., Daddario, N., Appendino, G., Marzo, V. D., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211231200 · Cited by 345

The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

Petrosino, S., & Marzo, V. D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13580 · Cited by 340

Chemical Basis of Hashish Activity

Mechoulam, R., Shani, A., Edery, H., & Grunfeld, Y. (1970) · Science · doi:10.1126/science.169.3945.611 · Cited by 331

Controlled clinical trial of cannabidiol in Huntington's disease

Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324

Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission

Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi‐Agrò, A., & Maccarrone, M. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-16-06900.2002 · Cited by 321

Pregnenolone Can Protect the Brain from Cannabis Intoxication

Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, É., Monlezun, S., Martín‐García, E., Kasanetz, F., Baillie, G. L., Panin, F., Cathala, A., et al. (2014) · Science · doi:10.1126/science.1243985 · Cited by 321

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties

García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320

Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

Arévalo‐Martín, Á., Vela, J. M., Molina‐Holgado, E., Borrell, J. I., & Guaza, C. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02511.2003 · Cited by 316

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández‐Tiedra, S., Salazar‐Roa, M., García-Taboada, E., Barcia, J. A., Guzmán, M., & Velasco, G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0688 · Cited by 309

Inhibition of tumor angiogenesis by cannabinoids

Blázquez, C., Casanova, M., Planas, A. M., del Pulgar, T. G., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 304

Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus

Stempel, A. V., Stumpf, A., Zhang, H., ÖZDOĞAN, T., Pannasch, U., Theis, A.-K., Otte, D.-M., Wojtalla, A., Rácz, I., Ponomarenko, A. A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.034 · Cited by 304

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

Marzo, V. D., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303

Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Little, P., Compton, D. M., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13256-4 · Cited by 290

Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains

Westlake, T. M., Howlett, A. C., Bonner, T. I., Matsuda, L. A., & Herkenham, M. A. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90511-8 · Cited by 290

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285

Gene therapy: can neural stem cells deliver?

Müller, F.-J., Snyder, E. Y., & Loring, J. F. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1829 · Cited by 282

The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors

Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279

Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease

Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y., Teng, Z., & Chen, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.030 · Cited by 277

Monoacylglycerol Lipase Exerts Dual Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer

Nomura, D. K., Lombardi, D. P., Chang, J. W., Niessen, S., Ward, A. M., Long, J. Z., Hoover, H. H., & Cravatt, B. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.009 · Cited by 275

Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.

Maas, A., Murray, G., Henney, H., Kassem, N., Legrand, V., Mangelus, M., Muizelaar, J., Stocchetti, N., & Knoller, N. (2006) · Lancet Neurology · doi:10.1016/s1474-4422(05)70253-2 · Cited by 272

The Role of the Endocannabinoid System in the Brain–Gut Axis

Sharkey, K. A., & Wiley, J. W. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.015 · Cited by 264

Molecular Pharmacology of Phytocannabinoids

Turner, S. E., Williams, C. M., Iversen, L. L., & Whalley, B. J. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_3 · Cited by 264

Astroglial CB1 Receptors Determine Synaptic D-Serine Availability to Enable Recognition Memory

Robin, L. M., Oliveira da Cruz, J. F., Langlais, V. C., Martin-Fernandez, M., Metna-Laurent, M., Busquets-Garcia, A., Bellocchio, L., Soria-Gomez, E., Papouin, T., Varilh, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.034 · Cited by 262

Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in Mice

Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T., Lutz, B., & Marsicano, G. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050269 · Cited by 261

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

Jones, N. A., Glyn, S., Akiyama, S., Hill, T. D. M., Hill, A. J., Weston, S. E., Burnett, M. D. A., Yamasaki, Y., Stephens, G. J., Whalley, B. J., et al. (2012) · Seizure · doi:10.1016/j.seizure.2012.03.001 · Cited by 257

Cannabinoid CB1and CB2Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis

Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256

The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells

Esposito, G., Filippis, D. D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252

Synaptic functions of endocannabinoid signaling in health and disease

Araque, A., Castillo, P. E., Manzoni, O. J., & Tonini, R. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.017 · Cited by 252

TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice

Marrone, M. C., Morabito, A., Giustizieri, M., Chiurchiù, V., Leuti, A., Mattioli, M., Marinelli, S., Riganti, L., Lombardi, M., Murana, E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15292 · Cited by 250

Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents

Nabissi, M., Morelli, M. B., Santoni, M., & Santoni, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs328 · Cited by 248

Synthetic cannabinoid WIN55,212‐2 inhibits generation of inflammatory mediators by IL‐1β‐stimulated human astrocytes

Sheng, W. S., Hu, S., Min, X. M., Cabral, G. A., Lokensgard, J. R., & Peterson, P. K. (2004) · Glia · doi:10.1002/glia.20108 · Cited by 246

Loss of cannabinoid receptors in the substantia nigra in huntington's disease

Glass, M., Faull, R. L. M., & Dragunow, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90352-g · Cited by 235

Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility

Franklin, A., Parmentier‐Batteur, S., Walter, L. M., Greenberg, D. A., & Stella, N. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07767.2003 · Cited by 232

The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines

Panikashvili, D., Shein, N. A., Mechoulam, R., Trembovler, V., Kohen, R., Alexandrovich, A. G., & Shohami, E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.004 · Cited by 229

Cannabinoid activation of PPARα; a novel neuroprotective mechanism

Sun, Y., Alexander, S. P. H., Garle, M. J., Gibson, C. L., Hewitt, K. N., Murphy, S. P., Kendall, D. A., & Bennett, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707478 · Cited by 229

Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects

Wallace, M. J., Wiley, J. L., Martin, B. R., & DeLorenzo, R. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01243-2 · Cited by 229

Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice

Parmentier‐Batteur, S., Jin, K., Mao, X. O., Xie, L., & Greenberg, D. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09771.2002 · Cited by 226

Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine 1A Receptor–Dependent Mechanism

Mishima, K., Hayakawa, K., Abe, K., Ikeda, T., Egashira, N., Iwasaki, K., & Fujiwara, M. (2005) · Stroke · doi:10.1161/01.str.0000163083.59201.34 · Cited by 225

A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease

Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223

Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels

van der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., Filippis, D. D., Micale, V., Steardo, L., Drago, F., Iuvone, T., et al. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6037-3 · Cited by 223

Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses

Sylantyev, S., Jensen, T. P., Ross, R. A., & Rusakov, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211204110 · Cited by 219

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

Marzo, V. D. (2000) · The FASEB Journal · doi:10.1096/fj.14.10.1432 · Cited by 219

Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection

Zarruk, J. G., Fernández‐López, D., García‐Yébenes, I., García‐Gutiérrez, M. S., Vivancos, J., Nombela, F., Torres, M., Burguete, M. C., Manzanares, J., Lizasoaín, I., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.631044 · Cited by 217

A FAAH-Regulated Class of N- Acyl Taurines That Activates TRP Ion Channels

Saghatelian, A., McKinney, M. K., Bandell, M., Patapoutian, A., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi0608008 · Cited by 216

High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients

Pisani, A., Fezza, F., Galati, S., Battista, N., Napolitano, S., Finazzi‐Agrò, A., Bernardi, G., Brusa, L., Pierantozzi, M., Stanzione, P., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20462 · Cited by 213

Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases

Russo, R., Cristiano, C., Avagliano, C., Caro, C. D., Rana, G. L., Raso, G. M., Canani, R. B., Meli, R., & Calignano, A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170216113756 · Cited by 213

The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., & Prather, P. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04346.x · Cited by 212

Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ 9 ‐THCV in animal models of Parkinson's disease

García, C., Palomo‐Garo, C., Garcı́a-Arencibia, M., Ramos, J., Pertwee, R. G., & Fernández‐Ruíz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01278.x · Cited by 211

CB 2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AβPP/PS1 Mice

Aso, E., Juvés, S., Maldonado, R. J., & Ferrer, I. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130137 · Cited by 211

Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease

Mulder, J., Zilberter, M. Y., Pasquaré, S. J., Alpár, A., Schulte, G., Ferreira, S. G., Köfalvi, A., Martín-Moreno, A. M., Keimpema, E., Tanila, H., et al. (2011) · Brain · doi:10.1093/brain/awr046 · Cited by 211

Regulation of gut luminal serotonin by commensal microbiota in mice

Hata, T., Asano, Y., Yoshihara, K., Kimura-Todani, T., Miyata, N., Zhang, X.-T., Takakura, S., Aiba, Y., Koga, Y., & Sudo, N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180745 · Cited by 211

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

Gómez‐Gálvez, Y., Palomo‐Garo, C., Fernández‐Ruíz, J., & García, C. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.017 · Cited by 210

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis

Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., et al. (2007) · Brain · doi:10.1093/brain/awm160 · Cited by 207

Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures

Chen, K., Ratzliff, A., Hilgenberg, L. G. W., Gulyás, A. I., Freund, T. F., Smith, M., Dinh, T. P., Piomelli, D., Mackie, K., & Soltész, I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00499-9 · Cited by 204

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

Devinsky, O., Verducci, C., Thiele, E. A., Laux, L. C., Patel, A. D., Filloux, F. M., Szaflarski, J. P., Wilfong, A. A., Clark, G., Park, Y. D., et al. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.05.013 · Cited by 203

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 mice

Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben‐Nun, A., Juknat, A., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01379.x · Cited by 201

Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target

Cassano, T., Calcagnini, S., Pace, L., Marco, F. D., Romano, A., & Gaetani, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00030 · Cited by 200

A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

van der Stelt, M., Fox, S. H., Hill, M. P., Crossman, A. R., Petrosino, S., Marzo, V. D., & Brotchie, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.04-3010fje · Cited by 199

Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1

Stock, K., Kumar, J., Synowitz, M., Petrosino, S., Imperatore, R., Smith, E. S. J., Wend, P., Purfürst, B., Nuber, U. A., Gurok, U., et al. (2012) · Nature Medicine · doi:10.1038/nm.2827 · Cited by 198

Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice

Cheng, D., Spiro, A. S., Jenner, A. M., Garner, B., & Karl, T. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140921 · Cited by 196

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors

Morgese, M. G., Cassano, T., Cuomo, V., & Giuffrida, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.021 · Cited by 195

GPR119 as a fat sensor

Hansen, H. S., ROSENKILDE, M. M., Holst, J. J., & Schwartz, T. W. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.014 · Cited by 189

Distribution of the Endocannabinoid System in the Central Nervous System

Hu, S. S., & Mackie, K. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_3 · Cited by 187

Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area

Mátyás, F., Urbán, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., & Katona, I. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.028 · Cited by 187

Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.

Feigenbaum, J. J., Bergmann, F., Richmond, S. A., Mechoulam, R., Nadler, V., Kloog, Y., & Sokolovsky, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9584 · Cited by 183

CB 1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition

Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A. G., & Shohami, E. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600047 · Cited by 180

Cannabidivarin is anticonvulsant in mouse and rat

Hill, A. G., Mercier, M., Hill, T., Glyn, S., Jones, N., Yamasaki, Y., Futamura, T., Duncan, M., Stott, C., Stephens, G. J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02207.x · Cited by 179

Anti-inflammatory lipoxin A 4 is an endogenous allosteric enhancer of CB 1 cannabinoid receptor

Pamplona, F. A., Ferreira, J., de Lima, O. M., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202906109 · Cited by 178

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study

Szaflarski, J. P., Bebin, E. M., Cutter, G., DeWolfe, J. L., Dure, L. S., Gaston, T. E., Kankirawatana, P., Liu, Y., Singh, R. K. R., Standaert, D. G., et al. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.07.020 · Cited by 178

Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors

Bauer, M., Chicca, A., Tamborrini, M., Eisen, D., Lerner, R., Lutz, B., Poetz, O., Pluschke, G., & Gertsch, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382481 · Cited by 175

Critical Role of Angiotensin II in Excess Salt-Induced Brain Oxidative Stress of Stroke-Prone Spontaneously Hypertensive Rats

Kim‐Mitsuyama, S., Yamamoto, E., Tanaka, T., Zhan, Y., Izumi, Y., Izumiya, Y., Ioroi, T., Wanibuchi, H., & Iwao, H. (2005) · Stroke · doi:10.1161/01.str.0000163084.16505.e3 · Cited by 173

CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling

Palazuelos, J., Ortega, Z., Díaz-Alonso, J., Guzmán, M., & Galve‐Roperh, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.291294 · Cited by 173

Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota

Geurts, L., Everard, A., Hul, M. V., Essaghir, A., Duparc, T., Matamoros, S., Plovier, H., Castel, J., Denis, R., Bergiers, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7495 · Cited by 172

Anandamide, an endogenous cannabinomimetic eicosanoid: ‘Killing two birds with one stone’

Marzo, V. D., & Fontana, A. (1995) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(95)90077-2 · Cited by 172

Tetrahydrocannabinol for neuropsychiatric symptoms in dementia

van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R., Kramers, C., Feuth, T. B., Rosenberg, P. B., van der Marck, M. A., & Rikkert, M. G. M. O. (2015) · Neurology · doi:10.1212/wnl.0000000000001675 · Cited by 170

Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice

Bilsland, L. G., Dick, J. R. T., Pryce, G., Petrosino, S., Marzo, V. D., Baker, D., & Greensmith, L. (2006) · The FASEB Journal · doi:10.1096/fj.05-4743fje · Cited by 168

Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice

Denovan‐Wright, E. M., & Robertson, H. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00157-3 · Cited by 168

Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity

Mehrpouya‐Bahrami, P., Chitrala, K. N., Ganewatta, M. S., Tang, C., Murphy, E. A., Enos, R. T., Velázquez, K. T., McCellan, J., Nagarkatti, M., & Nagarkatti, P. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15154-6 · Cited by 168

Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Fox, S. H., Henry, B., Hill, M. P., Crossman, A. R., & Brotchie, J. M. (2002) · Movement Disorders · doi:10.1002/mds.10289 · Cited by 165

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

López-Sendón, J. L., Caldentey, J. G., Cubillo, P. T., Romero, C. R., Ribas, G. G., Arias, M. A. A. A., de Yébenes, M. J. G., Tolón, R. M., Galve‐Roperh, I., Sagredo, O., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8145-9 · Cited by 162

A pilot study using nabilone for symptomatic treatment in Huntington's disease

Curtis, A., Mitchell, I., Patel, S., Ives, N. J., & Rickards, H. E. (2009) · Movement Disorders · doi:10.1002/mds.22809 · Cited by 161

A restricted population of CB 1 cannabinoid receptors with neuroprotective activity

Chiarlone, A., Bellocchio, L., Blázquez, C., Resel, E., Gómez, E. S., Cannich, A., Ferrero, J. J., Sagredo, O., Benito, C., Romero, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400988111 · Cited by 160

Monoacylglycerols Activate TRPV1 – A Link between Phospholipase C and TRPV1

Zygmunt, P. M., Ermund, A., Movahed, P., Andersson, D. A., Simonsen, C., Jönsson, B., Blomgren, A., Birnir, B., Bevan, S., Eschalier, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081618 · Cited by 157

The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model

Scott, K. A., Dalgleish, A. G., & Liu, W. M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0402 · Cited by 155

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice

Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., & Ferrer, I. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141014 · Cited by 154

Cannabidiol stimulates A ml‐1a‐dependent glial differentiation and inhibits glioma stem‐like cells proliferation by inducing autophagy in a TRPV 2‐dependent manner

Nabissi, M., Morelli, M. B., Amantini, C., Liberati, S., Santoni, M., Ricci‐Vitiani, L., D, R. P. M., & Santoni, G. (2015) · International Journal of Cancer · doi:10.1002/ijc.29573 · Cited by 154

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor‐independent mechanism

Vaccani, A., Massi, P., Colombo, A., Rubino, T., & Parolaro, D. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706134 · Cited by 154

Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases

Gofshteyn, J. S., Wilfong, A. A., Devinsky, O., Bluvstein, J., Charuta, J., Ciliberto, M. A., Laux, L., & Marsh, E. D. (2016) · Journal of Child Neurology · doi:10.1177/0883073816669450 · Cited by 152

Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets

Alvarez, F. J., Lafuente, H., Rey-Santano, M. C., Mielgo, V., Gastiasoro, E., Rueda, M. A., Pertwee, R. G., Castillo, A. I., Romero, J., & Martínez-Orgado, J. A. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e318186e5dd · Cited by 151

Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function

Pazos, M. R., Cinquina, V., Gómez, A., Layunta, R., Santos, M., Fernández‐Ruíz, J., & Martínez-Orgado, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.034 · Cited by 151

Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1481066 · Cited by 151

Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease

López, A., Aparicio, N., Pazos, M. R., Grande, M. T., Barreda-Manso, M. A., Benito‐Cuesta, I., Vázquez, C., Amores, M., Ruiz‐Pérez, G., García-García, E., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1174-9 · Cited by 151

Therapeutic potential of cannabis-related drugs

Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149

Palmitoylethanolamide Protects Against the Amyloid-β25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease

D’Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., & Calignano, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.25 · Cited by 149

Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors

Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147

Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., & Cuzzocrea, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041880 · Cited by 144

Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

Lastres‐Becker, I., de Miguel, R., PETROCELLIS, L. D., Makriyannis, A., Marzo, V. D., & Fernández‐Ruíz, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01595.x · Cited by 143

Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia

Muthian, S., Rademacher, D. J., Roelke, C. T., Gross, G. J., & Hillard, C. J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.044 · Cited by 143

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice

Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0304-z · Cited by 143

Cannabinoids Induce Glioma Stem-like Cell Differentiation and Inhibit Gliomagenesis

Aguado, T., Carracedo, A., Julien, B., Velasco, G., Milman, G., Mechoulam, R., Álvarez, L., Guzmán, M., & Galve‐Roperh, I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608900200 · Cited by 140

Oxidative Metabolism of Endocannabinoids by COX-2

Kozak, K. R., Prusakiewicz, J. J., & Marnett, L. J. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453081 · Cited by 136

The role of cannabinoids in adult neurogenesis

Prenderville, J. A., Kelly, A. M., & Downer, E. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13186 · Cited by 136

An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease

Jung, K., Astarita, G., Yaşar, S., Vasilevko, V., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.012 · Cited by 136

Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease

Bouchard, J. J., Truong, J. K., Bouchard, K. E., Dunkelberger, D. L., Desrayaud, S., Moussaoui, S. M., Tabrizi, S. J., Stella, N., & Muchowski, P. J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4008-12.2012 · Cited by 135

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

Cabranes, A., Venderová, K., de Lago, E., Fezza, F., Sánchez, A., Mestre, L., Valenti, M., García‐Merino, A., Ramos, J. A., Marzo, V. D., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.002 · Cited by 135

Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor

Guida, F., Luongo, L., Boccella, S., Giordano, M., Romano, R., Bellini, G., Manzo, I., Furiano, A., Rizzo, A., Imperatore, R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00342-1 · Cited by 133

CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease

Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.100 · Cited by 126

CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury

Zhang, M., Adler, M. W., Abood, M. E., Ganea, D., Jallo, J., & Tuma, R. F. (2009) · Microvascular Research · doi:10.1016/j.mvr.2009.03.005 · Cited by 124

Selective Inhibition of Alpha/Beta-Hydrolase Domain 6 Attenuates Neurodegeneration, Alleviates Blood Brain Barrier Breakdown, and Improves Functional Recovery in a Mouse Model of Traumatic Brain Injury

Tchantchou, F., & Zhang, Y. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2012.2647 · Cited by 123

Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine

Navarrete, F., Rodríguez‐Arias, M., Martín‐García, E., Navarro, D., García‐Gutiérrez, M. S., Aguilar, M. A., Aracil-Fernández, A., Berbel, P. J., Miñarro, J., Maldonado, R. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.157 · Cited by 122

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

Laere, K. V., Casteels, C., Lunskens, S., Goffin, K. E., Grachev, I. D., Bormans, G. M., & Vandenberghe, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.009 · Cited by 120

Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling

Moreno, E., Andradas, C., Medrano, M., Caffarel, M. M., Pérez-Gómez, E., Blasco-Benito, S., Gómez‐Cañas, M., Pazos, M. R., Irving, A. J., Lluı́s, C., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.561761 · Cited by 120

Biology and therapeutic potential of cannabinoid CB2receptor inverse agonists

Lunn, C. A., Reich, E., Fine, J. S., Lavey, B. J., Kozlowski, J. A., Hipkin, R. W., Lundell, D. J., & Bober, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707480 · Cited by 120

Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade

Mazzola, C., Micale, V., & Drago, F. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.026 · Cited by 118

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

Patti, F., Messina, S., Solaro, C. M., Amato, M. P., Bergamaschi, R., Bonavita, S., Bossio, R. B., Morra, V. B., Costantino, G., Cavalla, P., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312591 · Cited by 116

Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain

Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V., & Di Marzo, V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.11.047 · Cited by 115

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents

Griebel, G., Pichat, P., Beeské, S., Leroy, T., Redon, N., Jacquet, A., Françon, D., Bert, L., Even, L., Lopez‐Grancha, M., et al. (2015) · Scientific Reports · doi:10.1038/srep07642 · Cited by 113

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Aymerich, M. S., Aso, E., Abellanas, M. A., Tolón, R. M., Ramos, J. A., Ferrer, I., Romero, J., & Fernández‐Ruíz, J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.016 · Cited by 113

Endocannabinoids accumulate in spinal cord of SOD1G93A transgenic mice

Witting, A., Weydt, P., Hong, S. Y., Kliot, M., Möller, T., & Stella, N. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02544.x · Cited by 112

2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain

Nakane, S., Oka, S., Arai, S., Waku, K., Ishima, Y., Tokumura, A., & Sugiura, T. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00038-3 · Cited by 112

Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease

González-Aparicio, R., & Moratalla, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.008 · Cited by 112

Release of Fatty Acid Amides in a Patient With Hemispheric Stroke

Schäbitz, W.-R., Giuffrida, A., Berger, C., Aschoff, A. A., Schwaninger, M., Schwab, S., & Piomelli, D. (2002) · Stroke · doi:10.1161/01.str.0000023491.63693.18 · Cited by 111

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease

Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.06.014 · Cited by 111

ABHD6 Blockade Exerts Antiepileptic Activity in PTZ-Induced Seizures and in Spontaneous Seizures in R6/2 Mice

Naydenov, A. V., Horne, E. A., Cheah, C. S., Swinney, K., Hsu, K., Cao, J. K., Marrs, W., Blankman, J. L., Tu, S., Cherry, A. E., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.030 · Cited by 111

Invited Review: From nose to gut – the role of the microbiome in neurological disease

Bell, J. S., Spencer, J. I., Yates, R. L., Yee, S. A., Jacobs, B. M., & DeLuca, G. C. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12520 · Cited by 111

Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide

Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., & Docagne, F. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06377.x · Cited by 109

Increased Expression of TRPV1 in the Cortex and Hippocampus from Patients with Mesial Temporal Lobe Epilepsy

Sun, F., Guo, W., Zheng, D.-H., Zhang, C., Li, S., Liu, S., Yin, Q., Yang, H., & Shu, H. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9878-2 · Cited by 106

A cannabinoid type 2 receptor agonist attenuates blood–brain barrier damage and neurodegeneration in a murine model of traumatic brain injury

Amenta, P. S., Jallo, J., Tuma, R. F., & Elliott, M. B. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23114 · Cited by 106

The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus

Veilleux, A., Marzo, V. D., & Silvestri, C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1248-9 · Cited by 105

The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury

Tchantchou, F., Tucker, L. B., Fu, A. H., Bluett, R. J., McCabe, J. T., Patel, S., & Zhang, Y. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.006 · Cited by 103

Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease

Lastres‐Becker, I., Berrendero, F., Lucas, J. J., Martı́n-Aparicio, E., Yamamoto, A., Ramos, J. A., & Fernández‐Ruíz, J. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03403-5 · Cited by 103

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

Fernández‐Espejo, E., Caraballo, I., de Fonseca, F. R., Banoua, F. E., Ferrer, B., Flores, J. A., & Galán-Rodríguez, B. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.015 · Cited by 102

Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys

Cao, X., Li, L., Hadcock, J. R., Iredale, P. A., Griffith, D. A., Menniti, F. S., Factor, S. A., Greenamyre, J. T., & Papa, S. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125666 · Cited by 101

Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke

Ceprián, M., Jiménez-Sánchez, L., Vargas, C. A., Barata, L., Hind, W. H., & Martínez-Orgado, J. A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.017 · Cited by 101

Treatment of Tourette Syndrome with Cannabinoids

Müller‐Vahl, K. (2013) · Behavioural Neurology · doi:10.1155/2013/294264 · Cited by 101

Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial

van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R., Feuth, T. B., van der Marck, M. A., & Rikkert, M. G. M. O. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.011 · Cited by 100

Plasma endocannabinoid levels in multiple sclerosis

Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V., Kendall, D. A., Barrett, D. A., & Constantinescu, C. S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.07.021 · Cited by 100

Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man

Stroke Study Group, Caltagirone, C., Cisari, C., Schievano, C., Paola, R. D., Cordaro, M., Bruschetta, G., Esposito, E., & Cuzzocrea, S. (2015) · Translational Stroke Research · doi:10.1007/s12975-015-0440-8 · Cited by 98

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor

Nguyen, T., Li, J., Thomas, B. F., Wiley, J. L., Kenakin, T., & Zhang, Y. (2016) · Medicinal Research Reviews · doi:10.1002/med.21418 · Cited by 98

Peroxisome Proliferator‐Activated Receptorsαandγare Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Blednov, Y. A., Benavidez, J. M., Black, M., Ferguson, L. B., Schoenhard, G. L., Goate, A., Edenberg, H. J., Wetherill, L. F., HESSELBROCK, V. M., Foroud, T., et al. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12610 · Cited by 97

Gut microbiome and health: mechanistic insights

de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388

Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis

Rusch, J. A., Layden, B. T., & Dugas, L. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130689 · Cited by 415

Bioactive lipids, inflammation and chronic diseases

Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 376

The effects of microglia-associated neuroinflammation on Alzheimer’s disease

Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 331

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

Legare, C. A., Raup‐Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 320

Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature

Dutta, R. (2021) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001049 · Cited by 1

Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders

Estrada, J. A., & Contreras, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200217140255 · Cited by 33

Discovery of the Endocannabinoid System: A Breakthrough in Neuroscience

Hassanzadeh, P. (2014) · Archives of Neuroscience · doi:10.5812/archneurosci.15030 · Cited by 3

Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs

Marzo, V. D., Bisogno, T., & PETROCELLIS, L. D. (2001) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.5.3.349 · Cited by 4

Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

Duncan, R. S., Riordan, S. M., Gernon, M. C., & Koulen, P. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382220 · Cited by 30